|
|
A Companion Diagnostic for Prognosis of Kidney Cancer
|
N43CO100135-000
|
$199,597
|
$199,597
|
Gillespie, John
|
20/20 GENE SYSTEMS, INC.
|
|
|
Novel Targeted Therapy for Breast Cancer
|
2R44CA124179-02A2
|
$575,793
|
$287,897
|
Serrero, Ginette
|
A AND G PHARMACEUTICAL, INC.
|
|
|
Mitochondrial Redox Control of Metastasis
|
1K99CA143229-01A1
|
$112,899
|
$39,515
|
Hempel, Nadine
|
ALBANY MEDICAL COLLEGE
|
|
|
Core Support for Cancer Center
|
3P30CA013330-38S2
|
$100,000
|
$7,000
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Core Support for Cancer Center
|
5P30CA013330-38
|
$3,927,232
|
$274,906
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Proton-coupled folate/antifolate transport
|
5R01CA082621-12
|
$537,037
|
$537,037
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Taxol: Mechanisms of Action and Resistance
|
2R01CA077263-10A2
|
$415,000
|
$415,000
|
HORWITZ, SUSAN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
H/D Exchange Coupled to MS to Study Drug-Induced Change in Microtuble Structure
|
5R01CA124898-04
|
$315,400
|
$315,400
|
HORWITZ, SUSAN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Chemical Modulation of Orphan Nuclear Receptor Function
|
5R01CA127231-02
|
$275,560
|
$275,560
|
MANI, SRIDHAR
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP
|
2U10CA014958-36
|
$127,404
|
$127,404
|
SPARANO, JOSEPH
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Expression-Based Multi-Gene Signatures for CRC Recurrence and Chemoselection
|
2R44CA119565-05
|
$999,610
|
$999,610
|
Sears, Christopher
|
AMBERGEN, INC
|
|
|
Community Clinical Oncology Program
|
2U10CA037422-23
|
$4,179,081
|
$1,086,561
|
BRUNER, DEBORAH
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Radiation Therapy Oncology Group
|
3U10CA021661-34S2
|
$1,198,505
|
$635,208
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Community Clinical Oncology Program Research Base
|
3U10CA037422-22S2
|
$28,500
|
$7,410
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Community Clinical Oncology Program Research Base
|
3U10CA037422-22S3
|
$1,208,966
|
$314,331
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Radiation Therapy Oncology Group
|
5U10CA021661-34
|
$12,451,705
|
$6,599,404
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
SBIR TOPIC 241 PHASE II: Platelet-based Nanoparticle Therapy for Prostate Cancer
|
N44CO100119-000
|
$999,642
|
$999,642
|
Zwick, Michael
|
ANDROBIOSYS, INC.:1150748
|
|
|
Drug Delivery Carriers Targeted to Breast Tumor by Fusion Phage Proteins
|
5R01CA125063-04
|
$387,477
|
$387,477
|
PETRENKO, VALERY
|
AUBURN UNIVERSITY AT AUBURN
|
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-21
|
$461,201
|
$207,540
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
|
NSABP Participating Sites
|
5U10CA118735-05
|
$53,618
|
$35,388
|
CHANG, JENNY
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Proteosome Inhibition Therapy for Hematologic Malignancy
|
5K23CA113775-05
|
$134,015
|
$134,015
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
2P30CA125123-04
|
$3,089,219
|
$30,892
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-03S6
|
$100,000
|
$1,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-04S1
|
$250,400
|
$2,504
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Translational Research in Breast Cancer
|
5P50CA058183-16
|
$2,300,000
|
$1,150,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Pediatric Clinical Oncology Research Training Program
|
3K12CA090433-09S1
|
$134,042
|
$26,808
|
Poplack, David
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Pediatric Clinical Oncology Research Training Program
|
5K12CA090433-09
|
$614,521
|
$122,904
|
Poplack, David
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Therapeutic Targeting of Breast Cancer Tumor Initiating Cells
|
1R01CA148761-01
|
$464,834
|
$153,395
|
Rosen, Jeffrey
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Improving the Efficacy of Dendritic Cell Vaccines
|
3P01CA084512-07S2
|
$200,000
|
$60,000
|
Banchereau, Jacques
|
BAYLOR RESEARCH INSTITUTE
|
|
|
Chemotherapeutic Agents with Enhanced Selectivity for the Tumor Microenvironment
|
1R01CA140674-01A1
|
$300,870
|
$300,870
|
PINNEY, KEVIN
|
BAYLOR UNIVERSITY
|
|
|
Virginia Mason Community Clinical Oncology Program
|
3U10CA035192-26S1
|
$487,529
|
$199,887
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
|
Eastern Cooperative Oncology Group
|
2U10CA080775-12
|
$104,956
|
$104,956
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Targeting PML for therapy in leukemia-initiating cells
|
1K99CA139009-01A1
|
$87,492
|
$28,872
|
Ito, Keisuke
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Optimizing localized therapy for primary liver cancer: a clinical trial and model
|
5K23CA139005-02
|
$169,209
|
$169,209
|
Miksad, Rebecca
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Targeting PML for leukemia therapy.
|
1R01CA142874-01
|
$473,271
|
$236,636
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Dendritic Cell/Leukemia Fusions and PD-1 Blockade for AML
|
1R21CA149987-01
|
$379,018
|
$379,018
|
ROSENBLATT, JACALYN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Rectifying defects in tumor vasculature to improve chemo- and radiation therapies
|
5R01CA129339-03
|
$352,750
|
$352,750
|
SENGER, DONALD
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Circulating Tumor Cells in Non-Small Cell Lung Cancer
|
5R01CA125653-04
|
$337,278
|
$337,278
|
Nieva, Jorge
|
BILLINGS CLINIC FOUNDATION
|
|
|
Development of recombinant rhTL1A protein for cancer treatment
|
1R43CA139745-01A2
|
$329,560
|
$329,560
|
Kim, Sunghee
|
BIOPOWERTECH
|
|
|
Cancer Control in Older Adults
|
5K05CA092395-10
|
$148,568
|
$148,568
|
SILLIMAN, REBECCA
|
BOSTON MEDICAL CENTER
|
|
|
Long-term Survivorship in Older Women with Early Stage Breast Cancer
|
5R01CA093772-07
|
$1,187,507
|
$593,754
|
SILLIMAN, REBECCA
|
BOSTON MEDICAL CENTER
|
|
|
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer
|
1R25CA153955-01
|
$387,817
|
$96,954
|
GOLDBERG, BENNETT
|
BOSTON UNIVERSITY
|
|
|
Combination Therapies for Cancer Treatment
|
2R01CA049248-20A1
|
$338,392
|
$338,392
|
WAXMAN, DAVID
|
BOSTON UNIVERSITY
|
|
|
Inducing Chromosomal Damage Responses in Pancreatic Cancer
|
5R21CA133654-02
|
$214,500
|
$214,500
|
Faller, Douglas
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
The fuel sensing enzyme AMPK in the pathogenesis of prostate cancer
|
3R01CA118918-04S1
|
$14,625
|
$14,625
|
Luo, Zhijun
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
The fuel sensing enzyme AMPK in the pathogenesis of prostate cancer
|
5R01CA118918-05
|
$224,058
|
$224,058
|
Luo, Zhijun
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Heat shock proteins in signaling and cancer
|
5R01CA081244-12
|
$355,597
|
$71,119
|
SHERMAN, MICHAEL
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Cancer and Leukemia Group B CCOP Research Base
|
2U10CA037447-26
|
$2,316,114
|
$1,134,896
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Cancer and Leukemia Group B
|
3U10CA031946-29S3
|
$8,129,333
|
$7,966,746
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Cancer and Leukemia Group B
|
7U10CA031946-29
|
$11,034,745
|
$10,814,050
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Total relevant funding to Chemotherapy for this search: $522,770,634
|
